BRPI0606321A2 - tetraidropiridinas 3,4,(5)-substituìdas - Google Patents

tetraidropiridinas 3,4,(5)-substituìdas

Info

Publication number
BRPI0606321A2
BRPI0606321A2 BRPI0606321-7A BRPI0606321A BRPI0606321A2 BR PI0606321 A2 BRPI0606321 A2 BR PI0606321A2 BR PI0606321 A BRPI0606321 A BR PI0606321A BR PI0606321 A2 BRPI0606321 A2 BR PI0606321A2
Authority
BR
Brazil
Prior art keywords
substituted
compound
treatment
tetrahydropyridine
disease
Prior art date
Application number
BRPI0606321-7A
Other languages
English (en)
Inventor
Keiichi Masuya
Osamu Irie
Atsuko Nihonyanagi
Atsushi Toyao
Takanori Kanazawa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0606321A2 publication Critical patent/BRPI0606321A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

TETRAIDROPIRIDINAS 3,4,(5)-SUBSTITUIDAS. A presente invenção refere-se a compostos orgânicos compostos de tetraidropiridina 3,4,(5)-substituida, estes compostos para o uso no tratamento diagnóstico e terapêutico de um animal de sangue quente, especialmente para o tratamento de uma doença que depende da atividade de renina; o uso de um composto desta classe para a preparação de uma formulação farmacêutica para o tratamento de uma doença que depende da atividade de renina; o uso de um composto desta classe no tratamento de uma doença que depende da atividade de renina; formulações farmacêuticas compreendendo um composto de tetraidropiridina 3,4,(5)-substituída e/ou um método de tratamento compreendendo administrar um composto de tetraidropiridina 3,4,(5)-substitu!da, um método para a fabricação de composto de tetraidropiridina 3,4,(5)-substituida e novos intermediários e etapas parciais para sua síntese. Os compostos de 3,4,(5)-tetraidropiridina substituida têm a fórmula 1 em que os substituintes e simbolos são como descritos no relatório descritivo.
BRPI0606321-7A 2005-01-14 2006-01-12 tetraidropiridinas 3,4,(5)-substituìdas BRPI0606321A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500784.4A GB0500784D0 (en) 2005-01-14 2005-01-14 Organic compounds
PCT/EP2006/000216 WO2006074924A1 (en) 2005-01-14 2006-01-12 3,4,(5)-substituted tetrahvdropyridines

Publications (1)

Publication Number Publication Date
BRPI0606321A2 true BRPI0606321A2 (pt) 2009-06-16

Family

ID=34224619

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606321-7A BRPI0606321A2 (pt) 2005-01-14 2006-01-12 tetraidropiridinas 3,4,(5)-substituìdas

Country Status (12)

Country Link
US (1) US20100029647A1 (pt)
EP (1) EP1841740A1 (pt)
JP (1) JP2008526910A (pt)
KR (1) KR20070094918A (pt)
CN (1) CN101103002A (pt)
AU (1) AU2006205877B2 (pt)
BR (1) BRPI0606321A2 (pt)
CA (1) CA2590898A1 (pt)
GB (1) GB0500784D0 (pt)
MX (1) MX2007008558A (pt)
RU (1) RU2007130791A (pt)
WO (1) WO2006074924A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
BRPI0620736A2 (pt) 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
EP1908471A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
SG182223A1 (en) 2007-06-25 2012-07-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
KR101403311B1 (ko) 2008-05-05 2014-06-05 액테리온 파마슈티칼 리미티드 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
MX2012005281A (es) * 2009-11-05 2012-06-19 Fibrostatin S L Inhibicion de gpbp utilizando peptidomimeticos q2.
CN103502221B (zh) 2011-03-18 2016-03-30 拜耳知识产权有限责任公司 N-(3-氨甲酰基苯基)-1h-吡唑-5-甲酰胺衍生物及其用于防治动物害虫的用途
WO2014042263A1 (ja) * 2012-09-14 2014-03-20 田辺三菱製薬株式会社 新規レニン阻害薬
TWI758241B (zh) 2015-01-13 2022-03-21 日商日產化學工業股份有限公司 反應混合物中之錫化合物之處理方法
CN110577974B (zh) * 2019-09-10 2021-07-20 杭州澳赛诺生物科技有限公司 手性3-羟基-1,2,3,6-四氢吡啶的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800409T1 (xx) * 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) * 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
JP4271148B2 (ja) * 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニー 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター
RU2005102002A (ru) * 2002-06-27 2005-09-20 Актелион Фармасьютиклз Лтд. (Ch) Новые производные тетрагидропиридина
JP2007523845A (ja) * 2003-04-29 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体
CA2540543A1 (en) * 2003-10-09 2005-05-06 Actelion Pharmaceuticals Ltd Tetrahydropyridine derivatives

Also Published As

Publication number Publication date
CN101103002A (zh) 2008-01-09
JP2008526910A (ja) 2008-07-24
GB0500784D0 (en) 2005-02-23
US20100029647A1 (en) 2010-02-04
RU2007130791A (ru) 2009-02-20
AU2006205877B2 (en) 2010-01-07
WO2006074924A8 (en) 2007-04-19
KR20070094918A (ko) 2007-09-27
WO2006074924A1 (en) 2006-07-20
EP1841740A1 (en) 2007-10-10
CA2590898A1 (en) 2006-07-20
MX2007008558A (es) 2007-08-14
AU2006205877A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
BRPI0519769A2 (pt) compostos orgÂnicos
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
NO20083315L (no) 3,5-substituert piperidin-bestanddeler som renin-inhibitorer
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
NO20073719L (no) Kjemiske forbindelser
BRPI0519443A2 (pt) composto orgÂnicos
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20082709L (no) Kjemiske forbindelser
NO20070566L (no) Azin-karboksamider som antikreftmiddel
BRPI0409109A (pt) novos compostos
NO20073367L (no) Makrolider
PE20081389A1 (es) Uso de profarmacos de analogos de gaba para tratar enfermedades
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR0315580A (pt) Derivados de metileno uréia
BRPI0606321A2 (pt) tetraidropiridinas 3,4,(5)-substituìdas
BRPI0606707A2 (pt) uréias dissubstituìdas como inibidores de quinase
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
BRPI0610205A2 (pt) piperidinas 3,4-substituìdas como inibidores da renina
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.